Privacy Statement   Terms & Conditions   Sitemap  
  Diseases   Research   About us  
TBE Meningococcal Disease Influenza Smallpox

  Post-exposure Prophylaxis

In nearly all patients, IgM and IgG antibodies can be detected at the time of presentation for medical care; the antibody titer may reach its maximum level by the first blood test. Thus, the administration of IgG concentrates is unlikely to be of benefit to the patientís immune defence at that time and is limited to administration for up to 48 hours after the tick bite. Therefore, IgG is not available any more in European countries. Especially in children the benefit-risk ratio may be negative and therefore, TBE immunoglobulin must not be used for post-exposure prophylaxis in children and adolescents up to the age of 14 years.

 » Printversion

  » find


Baxter Announces Final Phase I/II Data and Initiation of Phase III Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine
» read more

Baxter receives preparedness contract from Austrian Ministry of Health for Pandemic Influenza Vaccine
» read more

Baxter Announces Safety and Immunogenicity Results from Phase I/II Clinical Trial of Cell-Based Candidate H5N1 Pandemic Vaccine
» read more

Baxter Vaccines Industriestrasse 67, A-1221 Wien, Tel: +43-1-20100,